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Abstract
Studies of the type 3 secretion system (T3SS) in Pseudomonas aeruginosa isolates from chronically infected older children and adults with
cystic ﬁbrosis (CF) show a predominantly exoS+/exoU) (exoS+) genotype and loss of T3SS effector secretion over time. Relatively little
is known about the role of the T3SS in the pathogenesis of early P. aeruginosa infection in the CF airway. In this longitudinal study, 168
P. aeruginosa isolates from 58 children diagnosed with CF following newborn screening and 47 isolates from homes of families with or
without children with CF were genotyped by pulsed-ﬁeld gel electrophoresis (PFGE) and T3SS genotype and phenotype determined
using multiplex PCR and western blotting. Associations were sought between T3SS data and clinical variables and comparisons made
between T3SS data of clinical and environmental PFGE genotypes. Seventy-seven of the 92 clinical strains were exoS+ (71% secretors
(ExoS+)) and 15 were exoU+ (93% secretors (ExoU+)). Initial exoS+ strains were ﬁve times more likely to secrete ExoS than
subsequent exoS+ strains at ﬁrst isolation. The proportion of ExoS+ strains declined with increasing age at acquisition. No associations
were found between T3SS characteristics and gender, site of isolation, exacerbation, a persistent strain or pulmonary outcomes. Four-
teen of the 23 environmental strains were exoS+ (79% ExoS+) and nine were exoU+ (33% ExoU+). The exoU+ environmental strains
were signiﬁcantly less likely to secrete ExoU than clinical strains. This study provides new insight into the T3SS characteristics of P. aeru-
ginosa isolated from the CF airway early in life.
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Introduction
Pseudomonas aeruginosa pulmonary infection is the major
cause of morbidity and mortality in cystic ﬁbrosis (CF). Its
acquisition during early childhood is often intermittent and
cleared with antibiotics [1,2], but by adulthood 80% are
chronically infected [3]. Many host pathogen and environ-
mental factors inﬂuence the persistence and severity of infec-
tion [4]. Insight into the role of organism-speciﬁc traits
during infection could lead to novel strategies for preventing
acquisition and reducing the impact on CF lung disease.
The pathogenesis of acute P. aeruginosa infection depends
upon a functional Type 3 secreting system (T3SS) [5,6]. The
T3SS uses complex secretion and translocation machinery to
deliver effector proteins (ExoU, ExoS, ExoT, Exo Y) directly
into the target cell cytoplasm, where they subvert host cell
defences and signalling [7,8]. ExoS disrupts tight cell junc-
tions, has anti-phagocytic properties and is required for
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establishing infection, whereas the more cytotoxic ExoU is a
marker for acute infection and virulence in non-CF settings
[6,9]. Studies of P. aeruginosa isolates from chronically
infected adults and older children with CF show predomi-
nantly an exoS+/exoU) (exoS+) genotype and loss of secre-
tion over time [10–13]. However, little is known about the
role of T3SS in the pathogenesis of early lung infection by
P. aeruginosa in CF infants and young children.
This study tracks over the ﬁrst years of life the T3SS
genotype and phenotype of P. aeruginosa isolates infecting
children diagnosed with CF following newborn screening.
Isolates were genotyped by pulsed-ﬁeld gel electrophoresis
(PFGE) and associations sought between T3SS characteristics
and clinical variables. Comparisons were also made between
the T3SS characteristics of clinical and environmental P. aeru-
ginosa strains from homes of children with and without CF.
Materials and Methods
Clinical isolates
As part of the Australasian Cystic Fibrosis Bronchoalveolar
Lavage (ACFBAL) randomized controlled trial [14], 168
P. aeruginosa isolates collected between 1999 and 2006 from
58 children (26 males) aged 3–63 (mean 26) months from
four centres were available for testing. The isolates were
selected from 150 respiratory specimens: (i) 57 BAL ﬂuid
(35 children); (ii) 82 oropharyngeal (OP) swab (44 children);
and (iii) 11 sputum (9 children post-ACFBAL study) samples.
A median of two (range 1–18) isolates were tested per child;
22 children provided a single sample (a single isolate was
available from 19 samples) as they had only one infection epi-
sode over the collection period. The ethics committees of all
participating hospitals approved the study.
The ACFBAL study randomized infants diagnosed with CF
after newborn screening to either BAL-directed therapy or
standard care using clinical judgement and OP cultures [14].
The BAL-directed group underwent BAL at enrollment
before 6 months of age, and then with exacerbations requir-
ing hospitalization, if OP cultures grew P. aeruginosa, and after
P. aeruginosa eradication therapy. All subjects had OP cultures
during pulmonary exacerbations and after eradication therapy,
while each underwent BAL at age 5 years. Five children had
received anti-pseudomonal treatment within 96 h of sample
collection. Children with positive P. aeruginosa BAL (‡103 col-
ony-forming units/mL) or OP (standard group only) cultures
received 2 weeks of intravenous anti-pseudomonal antibiotics
followed by oral ciproﬂoxacin and tobramycin inhalation solu-
tion for 4 and 8 weeks, respectively. At the end of treatment,
the BAL-directed group of children had further BAL and OP
cultures, while those receiving standard care had OP cultures
alone. If P. aeruginosa persisted the eradication protocol was
repeated, but if this also failed to clear the pathogen the child
was categorized as chronically infected. Samples were pro-
cessed by hospital laboratories, and P. aeruginosa identiﬁed
using standard criteria before storage at )70C [15]. All sub-
jects had high-resolution computed tomography scans and
spirometry at age 5 years.
Environmental isolates
Forty-seven P. aeruginosa isolates from another study (45
from sinks, showers and toilets and two from air samples)
were tested. Forty-two isolates came from 11 CF homes
and ﬁve from four non-CF households in south-east Queens-
land. CF homes were identiﬁed from Brisbane children in the
ACFBAL study; control homes were those of staff and
friends without anyone with CF in the household. The med-
ian number of isolates was two (range 1–11) per home. Sam-
pling of CF homes was conducted when the child with CF
was stable clinically and not infected with P. aeruginosa.
Stored clinical and environmental isolates were later con-
ﬁrmed as P. aeruginosa by a duplex polymerase chain reaction
(PCR) assay [16].
Pseudomonas genotyping
PFGE was performed as described previously [17]. Strains
were identiﬁed using cluster analysis software (GelComparII;
Applied Maths, Ghent, Belgium) and the Tenover criteria [18].
T3SS effector genotype
Pseudomonas aeruginosa DNA was extracted using the High
Pure PCR Template Preparation Kit (Roche Diagnostics,
Sydney, Australia). A T3SS multiplex PCR assay identiﬁed the
presence of exoS, exoU, exoT and exoY genes [19]. PAO1
[20] (exoS+/exoU)) (exoS+) and PA14 [21] (exoS)/exoU+)
(exoU+) served as controls.
T3SS effector secretion phenotype
Low calcium induction of the T3SS. Overnight Luria-Bertani
(LB) broth cultures were subcultured 1:100 into LB broth
supplemented with ethyleneglycol-O,O¢-bis (2-aminoethyl)-N,
N, N¢, N¢-tetraacetic acid (ﬁnal concentration 5 mM); 1.3 ml
of a 6-h culture was centrifuged at 10 000 g for 10 min. Pro-
tein extracted using trichloracetic acid was electrophoresed
in 12% resolving/4% stacking acrylamide SDS-PAGE gels at
100 V for 2 h 30 min. An All-Blue Precision Plus Protein
Standard (Bio-Rad, Sydney, Australia) and a PA103 control
(ExoU and ExoT knockout) were included in each gel. Pro-
teins were transferred to PVDF membranes (Bio-Rad) over-
night using 30 V at 4C.
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Western blots. Western blots were performed using the
Western Breeze kit (Invitrogen, Melbourne, Australia) using
a 1:20 000 dilution of a rabbit polyclonal antiserum that
detects the T3SS effectors ExoS, ExoT and ExoU [22] (kindly
provided by B. Kazmierczak). Membranes were imaged with
Visionworks Version 3.0 (UVP Instruments, USA).
Statistical analysis
T3SS genotype distribution and proportions of secreting
strains were determined. Using t-test for continuous vari-
ables and Pearson’s chi-squared test for categorical vari-
ables, associations were sought between gender, initial or
subsequent strain, site of isolation (OP, BAL or both),
exacerbation, persistent genotype, age at ﬁrst acquisition
and age of acquisition of a P. aeruginosa strain and T3SS
genotype and phenotype. Associations were also sought
with pulmonary function (forced expiratory volume in 1-
second (FEV1) % predicted values) and structural lung
injury (total bronchiectasis component of the CF computed
tomography (CF-CT) score, a validated upgraded version
of the Brody-II score [23]) at age 5 years for exoU+ and
ExoS+ strains, respectively. Differences were also assessed
between clinical and environmental isolates. P. aeruginosa
strains were taken as T3SS+ if any of the isolates of a
genotype were secretors. Exacerbation status was deﬁned
at the time of sample collection. A persistent strain was
arbitrarily deﬁned as one detected continuously or inter-
mittently for at least 3 months. Odds ratios (ORs) and
95% conﬁdence intervals (95% CIs) for bivariate associa-
tions were estimated using general estimating equation
methods with robust standard-error estimation and
accounted for within-individual correlation of measures
over time. Chi-squared test for trend was used for the
analyses of trends in the prevalence of expression across
age groups. All analyses were conducted using the STATA
10.0 statistical package (STATA 10.0; StataCorp, College
Station, TX, USA).
Results
PFGE
Ninety-two genotypes were identiﬁed amongst the clinical
isolates. Three children harboured examples of clonal strains
circulating widely in mainland eastern Australian CF clinics
(one Aust-01 (AES-1) and two Aust-02 (AES-2)) [24,25]. As
transmissibility and other properties of these strains may
have biased results, analyses were repeated excluding Aust-
01 and Aust-02 and the results were similar (data not
shown). The 47 environmental isolates yielded 23 PFGE
genotypes (18 from CF and ﬁve from non-CF homes). In
two cases a clinical strain had the same genotype as a strain
from the corresponding child’s home.
T3SS effector genotypes
All clinical and environmental isolates had either an exoS+ or
an exoU+ genotype; none had both exoS and exoU genes and
all had exoT and exoY genes.
Clinical strains
Table 1 illustrates relationships between T3SS genotype and
phenotype and clinical variables. Overall, 75% of all strains
and 83% of initial strains secreted T3SS proteins. This
included 61 (66%) strains that were ExoT+, of which 60
were either ExoS+ or ExoU+. The PFGE genotype was iden-
tical in 10/13 instances where there were multiple isolates
from the same sample. All possessed the same T3SS effector
genotype and seven also had the same secreted T3SS effec-
tor phenotype.
Initial exoS+ strains were ﬁve times more likely to secrete
ExoS than subsequent exoS+ strains at ﬁrst isolation. This
effect was not due to antibiotic treatment (two of four
exoS+ strains from samples collected during treatment were
secreters and two non-secreters). There was no association
between T3SS characteristics and gender, site of isolation,
exacerbation or strain persistence. Of the 16 paired upper
and lower respiratory isolates collected contemporaneously
from individual patients, 13 paired isolates each had an indis-
tinguishable PFGE genotype. Moreover, all 13 had the same
T3SS effector genotype, while 12 had the same secreted
T3SS effector phenotype. When analysed as a continuous
variable, the proportion of ExoS secreting strains declined
with age at strain acquisition, but not at acquisition age of
the initial strain (Table 2). Neither association reached signif-
icance when age was analysed as a categorical variable
(Fig. 1).
Twenty children harboured 22 persistent strains (18 exoS+
and 4 exoU+; Table 3). The mean age of ﬁrst isolation was
27.3 (range 7–58) months. All but two patients had interven-
ing periods where P. aeruginosa was undetected. The mean
time of persistence was 16.3 (range 3–54) months (exoS+
mean 14.7, range 3–54 months; exoU+ mean 27.8, range 6–
40 months). Three strains stopped expressing ExoS over
time.
Of 81 strains from children with complete follow-up data,
44 were initial strains (35 secreting, nine non-secreting).
Twenty-ﬁve of 35 (71%) children with T3SS effector secret-
ing strains had subsequent infection(s) compared with 4/9
(44%) with non-secreting strains, although this was not statis-
tically signiﬁcant (OR = 3.13; 95% CI, 0.53–18.82).
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Having had an exoU+ strain did not predict P. aeruginosa
from BAL cultures (p 1.0) or body mass index (p = 0.428) at
study completion. Similarly, at age 5 years previous acquisi-
tion of an ExoS or ExoU secreting strain was not associated
with Total Score or CF-CT score. At age 5 years, children
with ExoS+ strains had lower % predicted FEV1 values than
those with ExoS) strains, but the association was not statis-
tically signiﬁcant (p 0.078).
Environmental strains
T3SS effector genotype and secretion phenotype.. Of the 23
strains identiﬁed, 14 (61%) were exoS+ and nine (39%)
exoU+; exoU+ strains were less common in CF than non-CF
homes (5/18 (28%) vs. 4/5 (80%)). Overall, 11/14 (79%)
strains were ExoS+ and 3/9 (33%) were ExoU+.
Clinical vs. environmental strains. Environmental strains were
three times more likely than clinical strains to have an exoU+
genotype (33% vs. 16%; OR = 3.17; 95% CI, 1.003–9.58).
The proportions of clinical and environmental strains secret-
ing ExoS+ were similar (71% vs. 79%). However, exoU+ envi-
ronmental strains were signiﬁcantly less likely than clinical
TABLE 1. Relationship between T3SS genotype and phenotype and clinical variables
Genotype Phenotype
No. of
strains
exoS+
n (%)
exoU+
n (%) OR (95% CI)
No. of ExoS+
Strains (% of all
exoS+ strains
n (%) OR (95%CI)
No. of ExoU+ strains
(% of all exoU+ strains
n (%)a
Total 92 77 (84) 15 (16) 55/77 (71) 14/15 (93)
Gender
Male (n = 26) 38 31 (82) 7 (18) 1.00 18 (58) 1.00 6 (86)
Female (n = 32) 54 46 (85) 8 (15) 1.34 (0.42–4.28) 37 (80) 2.83 (0.87–9.53) 8 (100.0)
Timing
Initial strains 52 44 (85) 8 (15) 1.00 36 (82) 1.00 7 (88)
Subsequent strains 40 33 (83) 7 (18) 0.83 (0.28–2.50) 19 (58) 0.20 (0.09–0.47) 7 (100.0)
Siteb
BAL only 31 28 (90) 3 (10) 1.00 20 (71) 1.00 3 (100.0)
BAL+OP 18 15 (83) 3 (17) 0.53 (0.10–2.98) 12 (80) 1.17 (0.30–4.52) 3 (100.0)
OP only 35 27 (77) 8 (23) 0.36 (0.09–1.50) 19 (70) 0.52 (0.17–1.72) 7 (87.5)
Exacerbation
No 19 17 (90) 2 (11) 1.00 11 (65) 1.00 2 (100.0)
Yes 73 60 (82) 13 (18) 0.57 (0.12–2.70) 44 (73) 1.33 (0.49–3.65) 12 (92.3)
Persistent strain
No 59 50 (85) 9 (15) 1.00 35 (70) 1.00 8 (88.9)
Yes 22 18 (81) 4 (18) 0.84 (0.23–3.10) 14 (78) 1.12 (0.37–3.44) 4 (100.0)
Unknownc 11 9 (82) 2 (18) 0.79 (0.15–4.16) 6 (67) 0.57 (0.17–1.88) 2 (100.0)
OR, odds ratio; 95% CI, 95% conﬁdence interval; OP, oropharyngeal; BAL, bronchoalveolar lavage.
aOR and CI not calculated for ExoU because of small numbers.
bEight strains from follow-up sputum samples were excluded from this analysis.
cAll from follow-up sputum samples.
TABLE 2. T3SS gene presence and ExoS secretion by age
No. of
strains
Mean age at ﬁrst
acquisition, in
months (SD) OR (95% CI)
No. of
strains
Mean age at
acquisition in
months (SD) OR (95% CI)
All strains 52 27.3 (14.7) 92 36.4 (24.2)
Gene presence
exoS 44 26.5 (13.9) 1.00 (0.95–1.05) 77 36.1 (24.4) 1.00 (0.98–1.02)
exoU 8 26.2 (14.9) 1.00 15 37.6 (24.0) 1.00
Secretion (ExoS strains)
Yes 36 24.8 (14.6) 0.97 (0.92–1.01) 55 32.1 (23.8) 0.98 (0.96–1.00)
No 8 32.8 (15.9) 1.00 22 46.0 (23.5) 1.00
100.0
80.0 80.0
66.7
100.0
78.6 84.6
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0.0
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FIG. 1. Age at ﬁrst acquisition and age at acquisition of each strain,
and ExoS secretion.
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TABLE 3. Characteristics of persistent strains
Age at infection (months)
PT SITE 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68
1 OP – – – – B12
ExoU+
– – – – – – – – B12
ExoU+
– –
BAL – – – – – – B12
ExoU+
– – B12
ExoU+
B12
ExoU+
B12
ExoU+
B12
ExoU+
– B12
ExoU+
–
2 OP – – B38
ExoS)
– – – – – – – – – – – – –
BAL – – – B38
ExoS+
– – – – – – – – – – – –
3 OP – – – – W3
ExoS)
W3
ExoS)
W3
ExoS)
– – – – – – – – –
BAL – – – – – – W3
ExoS)
– – – – – – – – –
4 OP – – – B6
ExoS+
B6
ExoS+
– – – – B6
ExoS+
– – – – – –
BAL – – – B6
ExoS+
B6
ExoS+
– B6
ExoS+
– – – – – – – – –
5 OP – – W1
ExoS+
– – – – – – – – – – – – –
BAL – – – – W1
ExoS+
– – – W1
ExoS+
– – – – – – –
6 OP – M1
ExoS+
M1
ExoS+
– – – – – – – – – – M1
ExoS+
– –
BAL M1
ExoS+
– – – – M1
ExoS+
– – – – – – – – – –
7 OP – – – M8
ExoS+
M8
ExoS+
M8
ExoS+
M8
ExoS+
M8
ExoS+
– – – – – – – –
BAL – – – – – – – – – – – – – – – –
8 OP – – – – – – – – – B13
ExoS)
– – – – – –
BAL – – – – – B13
ExoS+
– – – – – – – – – –
9 OP – – – – – – – – – – – – M13
ExoS)
M13
ExoS)
M13
ExoS)
–
BAL – – – – – – – – – – – – – M13
ExoS)
– –
10 OP – – – – – – – – – M6
ExoS+
– M6
ExoS)
– M6
ExoS)
M6
ExoS)
–
BAL – – – – – – – – – – – – M6
ExoS)
M6
ExoS)
– –
11 OP – – – – B4
ExoS)
B4
ExoS+
– – – – – – – – – –
BAL – B4
ExoS)
– – – – – – – – – – – – – –
12 OP – – – – – B15
ExoU+
– – – – – – – – – –
BAL – – – – – – – – – – – – – B15
ExoU+
– –
13 OP – – – – – W14
ExoU+
W14
ExoU+
– – – – – – – – –
BAL – – – – – – – – – – – – – – – –
14 OP – – – – – – – – – Aust-02
ExoS)
– – – – – Aust-02
ExoS)
BAL – – – – – – – – – – – – – – – –
15 OP – – – – – – B40
ExoS+
B40
ExoS+
B40
ExoS+
– – – – – – –
BAL – – – – – – – – – – – – – – – –
16 OP – – – – – B31
ExoS+
– B31
ExoS+
B31
ExoS+
– – – – – – –
BAL – – – – – – – – – – – – – – – –
17 OP – – – – M4
ExoU+
– – – – – – – M4
ExoU+
– – –
BAL – – – – – – – – – – – – – – – –
18 OP – – – – – M10
ExoS+
– – M10
ExoS+
– – – – – – –
BAL – – – – – – – – – – – – – – – –
19 OP – – – – – M13
ExoS+
M13
ExoS)
– – – – – – – – –
BAL – – – – – – – – – – – – – – – –
20 OP – – – – – – – – – – – – W21
ExoS+
W21
ExoS+
– –
BAL – – – – – – – – – – – – – – – –
Patients 1–13 were from the BAL arm of the ACFBAL study; patients 14–20 were from the standard arm of the study and did not have BAL samples taken until the comple-
tion of the ACFBAL study. Additional persistent exoS+ strains were isolated from patients 1 (ExoS+) and 8 (ExoS) Aust-02) after the completion of the ACFBAL study; three
strains (all exoS+) lost secretion over time; ﬁve (including Aust-02 from patients 8 and 20) were non-secretors and two were intermittent secretors.
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strains to secrete ExoU (33% vs. 93%; OR = 0.04; 95% CI,
0.001–0.54). One of two shared clinical and environmental
strains was exoU+ and all isolates were secretors. The other
was an exoS+ strain that lost secretion over the 12 months
of infection in the CF lung; environmental isolates were
secretion negative.
Discussion
Our access to longitudinal P. aeruginosa isolates from infants
diagnosed with CF shortly after birth has allowed new insight
into the T3SS characteristics of strains colonizing or infecting
the CF airway in the ﬁrst years of life. The mean age of ini-
tial isolation of P. aeruginosa at 27 months was consistent
with a recent longitudinal study indicating that almost all chil-
dren with CF have acquired P. aeruginosa on at least one
occasion by age 3 years [26]. The proportion of our initial
strains secreting T3SS effector proteins (83%) was consider-
ably higher than the 45% reported for ﬁrst isolates previ-
ously, where the mean age of diagnosis of CF was
14 months and the mean age of ﬁrst infection was
63 months [13]. As our data show a reduced proportion of
secreting strains with age, it seems likely that some children
in the previous study had acquired P. aeruginosa before CF
diagnosis. The dominance of the exoS+ genotype and univer-
sal presence of the exoT and exoY genes were consistent
with published CF data [10–13].
In CF, an inverse relationship is reported between dura-
tion of infection and the proportion of T3SS+ isolates [13].
Loss of secretion is thought to assist the organism evade
immune detection, which helps establish chronic infection.
However, in early childhood P. aeruginosa infection is fre-
quently intermittent, and recently introduced eradication
treatments delay the development of chronic infection [27].
In this study the proportional decline in ExoS+ status to 65%
in subsequent strains at ﬁrst isolation was unexpected. We
have previously reported that anti-pseudomonal antibiotics
can reduce exoenzyme levels [28]. However, there was no
evidence that the decline in ExoS+ status in this study was
due to antibiotics. Perhaps host defences are primed by ﬁrst
exposure so that subsequent infection does not initiate
secretion. Interestingly, exoU+ strains were almost equally
divided between initial and subsequent strains and only one
strain was ExoU). Few persistent strains lost secretion over
time, reﬂecting the young age of the cohort and the study’s
short time-frame.
We found no evidence that T3SS secretion was required
for, or facilitated, lower respiratory infection. However, 50%
of OP strains came from children in the standard arm of the
ACFBAL study who did not have BAL at the time of infec-
tion. Earlier, we showed that exoenzyme levels were higher
in hospitalized than non-hospitalized CF patients [28]. The
lack of association between T3SS secretion and exacerbation
in the present study may reﬂect limited non-exacerbation
samples or the very young age of the patients. Exacerbations
with chronic P. aeruginosa infection may differ from those
associated with early intermittent infection. Almost all of the
20 children with persistent strains had intervening periods of
microbiological clearance. There was no association between
T3SS characteristics and a persistent strain, and further stud-
ies are needed to differentiate true intermittent infection
characterized by clearance and re-infection from persistence
at levels below detection by routine microbiological tech-
niques.
ExoU secretion is associated with increased virulence in
non-CF settings [5,6,9,29]. Assessments of exoU+ and dis-
ease severity in CF are hampered by the dominance of exoS+
strains. There was no association between exoU+ and viru-
lence in this series (15 exoU+ strains), although the mean
time of persistence was longer for exoU+ than for exoS+
strains. There were indications of ExoS secretion predicting
subsequent infection and lower FEV1 as reported in one CF
study [13], but these associations did not reach statistical sig-
niﬁcance, possibly because of limited sample size.
The environment is the assumed P. aeruginosa reservoir
for most CF airway infections. Consistent with natural envi-
ronmental data [10], the proportion of exoU+ environmental
strains was double that of exoU+ clinical strains. Interestingly,
the overall proportion of ExoU and ExoS secreting environ-
mental strains was 61%, compared with 75% for clinical
strains and 90% for environmental strains reported previ-
ously [11]. This low rate was attributable to the low propor-
tion of secreting exoU+ strains (33% vs. 93% for exoU+
clinical strains). The lack of ExoU+ strains may reﬂect the
particular environmental niche, current climatic conditions or
small sample size.
This study has further deﬁned T3SS properties of P. aeru-
ginosa from the airways of CF infants. Initial and intermittent
infections remain a concern for young children with CF and
characterizing organism-speciﬁc traits inﬂuencing outcome
should help in the development of novel therapies to prevent
or delay the onset of CF lung disease.
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